CAJ | 학술논문

骨关节植入物%骨与关节循证医学%镇痛药%布比卡因%关节腔内%关节镜手术%术后止痛%安慰剂%随机对照试验%不良反应%Meta分析骨關節植入物%骨與關節循證醫學%鎮痛藥%佈比卡因%關節腔內%關節鏡手術%術後止痛%安慰劑%隨機對照試驗%不良反應%Meta分析
골관절식입물%골여관절순증의학%진통약%포비잡인%관절강내%관절경수술%술후지통%안위제%수궤대조시험%불량반응%Meta분석
bone and joint implants%evidence-based medicine of bone and joint%analgesic drugs%bupivacaine%intra-articular%arthroscopic surgery%postoperative analgesia%placebo%randomized control ed trial%adverse reactions%Meta-analysis

背景：关节镜治疗后疼痛不但影响患者的生活质量，而且不利于患者治疗后的早期合理锻炼以及功能恢复。截止至2012年，国内外共发表了18篇关于关节镜治疗后关节腔内注射布比卡因用于术后镇痛的随机安慰剂对照试验，结果却不尽相同。 　　目的：通过随机安慰剂对照试验的Meta分析，检验关节镜治疗后关节腔内注射布比卡因镇痛的有效性和安全性。 　　方法：通过MEDLINE，Cochrane library，谷歌学术数据库检索截止至2012年4月有关使用布比卡因关节腔内注射用于关节镜治疗后镇痛的随机对照试验。检索关键词包括“布比卡因，关节腔内，关节镜，术后疼痛，安慰剂”。 　　结果与结论：Meta分析共纳入18篇文献(n=934)(布比卡因组461例，安慰剂对照组473例)。结果显示，布比卡因组的目测类比评分数值较安慰剂对照组低(WMD：-1.39，95%CI：-2.17至-0.61，P<0.00001)，且需要追加镇痛药的患者数少(RR：0.84，95%CI：0.62-1.66，P=0.010)。布比卡因组与安慰剂对照组相比，首次需要追加镇痛药离术后关节腔内注射的时间更长(WMD：157.72，95%CI：16.43-299.01， P<0.00001)，并且2组不良反应发生率差异无显著性意义(RR：0.64，95%CI：0.29-1.44，P=0.48)。通过检索目前的相关文献发现，与安慰剂对照组相比，关节镜治疗后关节腔内注射布比卡因可以显著缓解疼痛且不增加并发症的发生率。
　　배경：관절경치료후동통불단영향환자적생활질량，이차불리우환자치료후적조기합리단련이급공능회복。절지지2012년，국내외공발표료18편관우관절경치료후관절강내주사포비잡인용우술후진통적수궤안위제대조시험，결과각불진상동。 　　목적：통과수궤안위제대조시험적Meta분석，검험관절경치료후관절강내주사포비잡인진통적유효성화안전성。 　　방법：통과MEDLINE，Cochrane library，곡가학술수거고검색절지지2012년4월유관사용포비잡인관절강내주사용우관절경치료후진통적수궤대조시험。검색관건사포괄“포비잡인，관절강내，관절경，술후동통，안위제”。 　　결과여결론：Meta분석공납입18편문헌(n=934)(포비잡인조461례，안위제대조조473례)。결과현시，포비잡인조적목측류비평분수치교안위제대조조저(WMD：-1.39，95%CI：-2.17지-0.61，P<0.00001)，차수요추가진통약적환자수소(RR：0.84，95%CI：0.62-1.66，P=0.010)。포비잡인조여안위제대조조상비，수차수요추가진통약리술후관절강내주사적시간경장(WMD：157.72，95%CI：16.43-299.01， P<0.00001)，병차2조불량반응발생솔차이무현저성의의(RR：0.64，95%CI：0.29-1.44，P=0.48)。통과검색목전적상관문헌발현，여안위제대조조상비，관절경치료후관절강내주사포비잡인가이현저완해동통차불증가병발증적발생솔。
BACKGROUND:Pain after arthroscopic treatment can not only affect the patient’s life quality, and is not conducive to the early reasonable exercise and functional recovery of the patients after treatment. Up to 2012, there are 18 randomized placebo-control ed trials on intra-articular injection of bupivacaine for analgesia after arthroscopic surgery, but the results are different. OBJECTIVE:To examine the efficacy and safety of intra-articular injection of bupivacaine in the management of pain after arthroscopic surgery through randomized placebo-control ed trials. METHODS:The MEDLINE database, Cochrane Central Register and Google Scholar database were retrieved for the randomized control ed trials on intra-articular injection of bupivacaine in the management of pain after arthroscopic surgery up to April 2012. The key words were“bupivacaine, intra-articular, arthroscopic, postoperative pain, placebo”. RESULTS AND CONCLUSION:Eighteen studies (n=934) were included (461 cases in bupivacaine group and 473 cases in the placebo control group). The Meta-analysis results showed the visual analog scale score of the bupivacaine group was lower than that of the placebo control group (weighted mean difference:-1.39, 95%confidence interval:-2.17 to-0.61, P<0.000 01), and the number of patients required supplementary analgesia was less than the placebo control group (relative risk:0.84, 95%confidence interval:0.62 to 1.66, P=0.010). The time from first supplementary analgesia to postoperative intra-articular injection in the bupivacaine group was longer that in the placebo control group (weighted mean difference:157.72, 95%confidence interval:16.43 to 299.01, P<0.000 01). There was no significant difference in the incidence of side effect between two groups (relative risk:0.64, 95%confidence interval:0.29 to 1.44, P=0.48). On the basis of the currently available literature, the intra-articular of bupivacaine after arthroscopic surgery can significantly relieve pain without increasing the adverse reactions when compared with the placebo control group.